Compare Bristol-Myers Squibb Co (BMY) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Upwork Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.33 (market cap $116.30B), while Upwork Inc trades at $9.19 (market cap $1.12B). The key difference: Bristol-Myers Squibb Co is far larger — about 103.8× Upwork Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| BMY | UPWK | |
|---|---|---|
Market Cap | $116.30B | $1.12B |
Sector | Health | Industrials |
52-Week High | $62.37 | $22.11 |
52-Week Low | $42.60 | $7.84 |
Enterprise Value | $152.24B | $915.11M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
UPWK trades at $9.12, up 3.4% today, with a bullish technical signal from moving averages. The company reported $787.78M revenue and $115.43M net income for 2025, with strong profitability margins. Recent news highlights AI integration initiatives and board refreshment, but multiple law firms are investigating potential securities law violations following earnings misses and a guidance cut.
The outlook is mixed: analyst consensus is a Buy with a $10.67 price target, but earnings misses and legal scrutiny pose risks. Revenue growth has slowed, and net cash flow turned negative in 2025. Upside depends on successful AI adoption and execution, while downside risks include ongoing investigations and competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
